Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

Click for more information

0.00%

8.0¢ kazia therapeutics limited

Ann: Novogen provides Cantrixil update-NRT.AX, page-19

First 19 Last

Share
Profile

Follow
37shamrock

102 Posts.

3

02/05/16

13:29

Post #: 17652300
Share

Originally posted by Pbnewby ↑

If the timeline was correct in 2015 for the drugs then there is no way known these delays would have taken this long - maybe 3 - 6 months delay but 12 months or more I think is saying "we may have been opptimistic with the timelines in 2014/15... another thing to consider is why would Yale be giving up 15% of its share in CanTx and hand over all the IP control to Novogen..

Anyone feel like we're slowly slowly being fed reality to come back down after the expectations of 2014/2015 during/before the CR.... even JG has attempted to lower our expectations...

The funny thing is we are taking out our frustrations against the current board - many of whom came after the CR campaign...

Expand

I don't quite understand all the implications. Who said Yale lose their 15% stake? Surely that would come with a price.
Does this announcement just mean that Yale's involvement is now no longer required, now the drug development for clinical trials is over?
Or does this mean with Yale now out of the equation they plan to partner up with a big Pharma?

NRT Price at posting: 12.0¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

HAS

Hastings progressing Yangibana to production with lower costs

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The iron ore comeback: Can it last?

There are more pages in this discussion • 14 more messages in this thread...

First 19 Last

Add KZA (ASX) to my watchlist